[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335693-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335693-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","co-inhibition-of-tgli1-and-gp130-using-fda-approved-ketoconazole-and-bazedoxifene-is-synergistic-against-the-growth-and-metastasis-of-her2-enriched-and-triple-negative-breast-cancers","Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers","","Breast cancer stem cells (CSCs) drive recurrence and metastasis and resist many therapies. tGLI1 and STAT3 are reported to be frequently co-expressed in HER2-enriched breast cancer and triple-negative breast cancer (TNBC), supporting cooperative gene regulation of CSCs. This work identifies co-overexpression and co-enrichment of tGLI1 with GP130 signaling and shows that tGLI1+IL-6R/GP130 activation is common in these aggressive subtypes compared with luminal tumors. FDA-approved ketoconazole (tGLI1 inhibitor) and bazedoxifene (GP130 inhibitor) act synergistically, suppressing proliferation and CSC phenotypes in vitro and reducing TNBC tumor growth and metastatic burden in vivo, supporting further clinical investigation of co-targeting tGLI1 and IL-6R/GP130/STAT3 pathways.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/co-inhibition-of-tgli1-and-gp130-using-fda-approved-ketoconazole-and-bazedoxifene-is-synergistic-against-the-growth-and-metastasis-of-her2-enriched-and-triple-negative-breast-cancers/335693/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/co-inhibition-of-tgli1-and-gp130-using-fda-approved-ketoconazole-and-bazedoxifene-is-synergistic-against-the-growth-and-metastasis-of-her2-enriched-and-triple-negative-breast-cancers/335693.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in breast cancer treatment?","Question",{"text":63,"@type":64},"Breast cancer stem cells (CSCs) are resistant to most therapies and contribute to tumor recurrence and metastasis. The study targets signaling that supports CSC-promoting transcriptional programs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which pathways and factors are co-targeted in this research?",{"text":68,"@type":64},"The study focuses on co-targeting tGLI1 and IL-6R/GP130 signaling, linked to STAT3 activation, which are frequently co-expressed and co-activated in HER2-enriched breast cancer and TNBC.",{"name":70,"@type":61,"acceptedAnswer":71},"How do ketoconazole and bazedoxifene affect cancer and CSC phenotypes?",{"text":72,"@type":64},"Ketoconazole (tGLI1 inhibitor) and bazedoxifene (GP130 inhibitor) synergize against breast cancer proliferation and CSC phenotypes in vitro. They also reduce TNBC tumor growth and metastatic burden in vivo.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335693,1790338251,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nCo-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers  \nSara Manore 1,2, Chuling Zhuang 1,3, Mariana K. Najjar 1,2,3, Grace L. Wong 1,2, Shivani Bindal 1, Kounosuke Watabe 4, Jiayuh Lin 5 and Hui-Wen Lo 1,2,3,4, *  \nCitation: Manore, S.; Zhuang, C.; Najjar, M.K.; Wong, G.L.; Bindal, S.; Watabe, K.; Lin, J.; Lo, H.-W.  \nCo-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells 2024, 13, 2087 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cells13242087  \nAcademic Editor: Ralf Weiskirchen  \nReceived: 8 November 2024  \nRevised: 9 December 2024  \nAccepted: 10 December 2024  \nPublished: 17 December 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; [manores2@winthropalumni.com](manores2@winthropalumni.com) (S.M.); [chuling.zhuang@uth.tmc.edu](chuling.zhuang@uth.tmc.edu) (C.Z.); [mariana.k.najjar@uth.tmc.edu](mariana.k.najjar@uth.tmc.edu) (M.K.N.); [glwong@houstonmethodist.org](glwong@houstonmethodist.org) (G.L.W.); [shivani.bindal@uth.tmc.edu](shivani.bindal@uth.tmc.edu) (S.B.)  \n2 Wake Forest Graduate School of Biomedical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA  \n3 Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA  \n4 Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA; [kwatabe@wakehealth.edu](kwatabe@wakehealth.edu)  \n5 Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; [jlin@som.umaryland.edu](jlin@som.umaryland.edu)  \n* [Correspondence: hui-wen.lo@uth.tmc.edu](Correspondence: hui-wen.lo@uth.tmc.edu)  \nAbstract: Breast cancer stem cells (CSCs) are resistant to most cancer therapeutics and contribute to tumor recurrence and metastasis. Two breast CSC-promoting transcription factors, truncated glioma-associated oncogene homolog 1 (tGLI1) and signal transducer and activator of transcription 3 (STAT3), have been reported to be frequently co-expressed in HER2-enriched breast cancer and triple-negative breast cancer (TNBC), undergo protein-protein interactions for gene regulation and activation, and functionally cooperate to promote breast CSCs. STAT3 can be activated by activated interleukin-6 receptor/glycoprotein-130 (IL-6R/GP130) . Co-targeting of tGLI1 and IL-6R/GP130 has not been investigated in breast cancer or any tumor type. Here, we report that tGLI1 and GP130 are co-overexpressed in the majority of HER2-enriched breast cancers and TNBCs at 53.8% and 44.4%, respectively. tGLI1+IL-6/IL-6R/GP130 signaling is frequently co-enriched and co-activated in HER2-enriched breast cancer and TNBC when compared to luminal subtypes. tGLI1+GP130 cooverexpression strongly promotes CSCs of HER2-enriched breast cancer and TNBC. FDA-approved tGLI1 inhibitor Ketoconazole and GP130 inhibitor Bazedoxifene synergize against breast cancer proliferation and CSC phenotypes in vitro and reduce TNBC tumor growth and metastatic burden in vivo. Our study demonstrates, for the first time, that co-targeting tGLI1 and IL-6R/GP130/STAT3 signaling pathways is synergistic against HER2-enriched breast cancer and TNBC, warranting future clinical investigations.  \nKeywords: t","cbCaiggSLIIjBeO9","https://ap.wps.com/l/cbCaiggSLIIjBeO9","pdf",5024312,25,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What problem does the study address in breast cancer treatment?\",\"answer\":\"Breast cancer stem cells (CSCs) are resistant to most therapies and contribute to tumor recurrence and metastasis. The study targets signaling that supports CSC-promoting transcriptional programs.\"},{\"question\":\"Which pathways and factors are co-targeted in this research?\",\"answer\":\"The study focuses on co-targeting tGLI1 and IL-6R/GP130 signaling, linked to STAT3 activation, which are frequently co-expressed and co-activated in HER2-enriched breast cancer and TNBC.\"},{\"question\":\"How do ketoconazole and bazedoxifene affect cancer and CSC phenotypes?\",\"answer\":\"Ketoconazole (tGLI1 inhibitor) and bazedoxifene (GP130 inhibitor) synergize against breast cancer proliferation and CSC phenotypes in vitro. They also reduce TNBC tumor growth and metastatic burden in vivo.\"}]","Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers | PDF",1790011960,63]